Jongmin Lee1, Michael Reding. 1. Department of Rehabilitation Medicine, and Center for Geriatric Neuroscience Research, Institute of Biomedical Science and Technology, University Hospital, Konkuk University, Seoul, South Korea.
Abstract
BACKGROUND AND PURPOSE: Anti-inflammatory therapy decreases infarct size and enhances stroke recovery. Thiazolidinedione peroxisome proliferator-activated receptor (PPAR)gamma agonists have potent anti-inflammatory and insulin-sensitizing anti-diabetic actions. METHODS: Thirty stroke patients with type 2 diabetes admitted for acute inpatient stroke rehabilitation receiving pioglitazone or rosiglitazone were matched for age, sex, initial FIM(TM) score and interval post-stroke with 30 stroke patients with type 2 diabetes not receiving thiazolidinediones. Relevant outcome variables were compared for both groups. RESULTS: The thiazolidinedione treated group showed significantly greater mean improvement in FIM(TM) score compared to control group (25.6 +/- 10.2 SD vs. 19.8 +/- 10.5, respectively, P = 0.015). There was no significant difference in length of rehabilitation hospital stay (24.2 +/- 7.6 vs. 25.1 +/- 7.4 days, P = 0.657) or final discharge destination (home/institution, 19/11 versus 17/13, P = 0.792). CONCLUSIONS: Use of thiazolidinediones was associated with enhanced functional recovery in stroke patients with type 2 diabetes.
BACKGROUND AND PURPOSE: Anti-inflammatory therapy decreases infarct size and enhances stroke recovery. Thiazolidinedione peroxisome proliferator-activated receptor (PPAR)gamma agonists have potent anti-inflammatory and insulin-sensitizing anti-diabetic actions. METHODS: Thirty strokepatients with type 2 diabetes admitted for acute inpatient stroke rehabilitation receiving pioglitazone or rosiglitazone were matched for age, sex, initial FIM(TM) score and interval post-stroke with 30 strokepatients with type 2 diabetes not receiving thiazolidinediones. Relevant outcome variables were compared for both groups. RESULTS: The thiazolidinedione treated group showed significantly greater mean improvement in FIM(TM) score compared to control group (25.6 +/- 10.2 SD vs. 19.8 +/- 10.5, respectively, P = 0.015). There was no significant difference in length of rehabilitation hospital stay (24.2 +/- 7.6 vs. 25.1 +/- 7.4 days, P = 0.657) or final discharge destination (home/institution, 19/11 versus 17/13, P = 0.792). CONCLUSIONS: Use of thiazolidinediones was associated with enhanced functional recovery in strokepatients with type 2 diabetes.
Authors: John A Dormandy; Bernard Charbonnel; David J A Eckland; Erland Erdmann; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene; Meng H Tan; Pierre J Lefèbvre; Gordon D Murray; Eberhard Standl; Robert G Wilcox; Lars Wilhelmsen; John Betteridge; Kåre Birkeland; Alain Golay; Robert J Heine; László Korányi; Markku Laakso; Marián Mokán; Antanas Norkus; Valdis Pirags; Toomas Podar; André Scheen; Werner Scherbaum; Guntram Schernthaner; Ole Schmitz; Jan Skrha; Ulf Smith; Jan Taton Journal: Lancet Date: 2005-10-08 Impact factor: 79.321